Muscle Invasive Bladder Cancer

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Asieris Pharmaceuticals
1 program
1
APL-1202 in combination with tislelizumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT04813107UnknownEst. Mar 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Asieris PharmaceuticalsAPL-1202 in combination with tislelizumab

Clinical Trials (1)

NCT04813107Asieris PharmaceuticalsAPL-1202 in combination with tislelizumab

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer

Start: Dec 2021Est. completion: Mar 2024
Phase 1/2Unknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space